$2.070
-0.030 (-1.43%)At close
GNPX News
GNPX Events
Genprex Announces Results from Reqorsa Clinical Analysis
Genprex announced results from a translational analysis of patients treated with its lead drug candidate, Reqorsa - quaratusugene ozeplasmid -, a gene therapy product. The data suggest that increased TUSC2 expression, the tumor suppressor gene used in Reqorsa, is associated with a systemic transcriptional shift toward cellular maintenance, repair and quality control, a profile consistent with enhanced cellular resilience to aging-associated stress. The findings were presented in a poster at the Gerontological Society of America 2026 Annual Scientific Meeting November 4-7 in National Harbor, Maryland. TUSC2 is a mitochondrial calcium-regulating protein whose expression declines with age, including in the human brain and other metabolically active tissues. Researchers used Reqorsa, designed to restore tumor-suppressor function, to study the blood's transcriptional response to increased TUSC2.
Genprex Collaborates with Roche Diagnostics to Validate Biomarkers for NSCLC
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. The collaboration leverages Roche Diagnostics' expertise in assay development. Roche Diagnostics received U.S. FDA Breakthrough Device Designation for the first AI-driven companion diagnostic for NSCLC that uses a TROP2 score to evaluate NSCLC specimens, and Genprex will use the same antibody against TROP2 for its validation studies. This strategic alignment ensures consistency and builds upon established diagnostic methods. Genprex is expanding on its preclinical and clinical studies to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies. Roche Diagnostics will perform the necessary assay validation using its TROP2 antibody. Genprex anticipates completing these validation studies by approximately the end of 2026, with subsequent integration into its NSCLC clinical program shortly thereafter, dependent on the results of the validation studies. This collaboration exemplifies Genprex's commitment to delivering innovation that enables more precise diagnosis and treatment strategies in oncology, ultimately aiming to improve outcomes for NSCLC patients.
Genprex Trading Halted, News Pending
Genprex trading halted, news pending
Genprex Receives Patent Allowance for Reqorsa Gene Therapy in Canada
Genprex announced that The Canadian Intellectual Property Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa Gene Therapy in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer and small cell lung cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore Europe, Korea, Australia and Israel.
Genprex Files $250M Mixed Securities Shelf
Genprex files $250M mixed securities shelf
Related articles
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.